Lenvatinib: Role in thyroid cancer and other solid tumors
Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodin...
Gespeichert in:
| Veröffentlicht in: | Cancer treatment reviews 2016-01, Vol.42, p.47-55 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 55 |
|---|---|
| container_issue | |
| container_start_page | 47 |
| container_title | Cancer treatment reviews |
| container_volume | 42 |
| creator | Cabanillas, Maria E Habra, Mouhammed Amir |
| description | Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodine-refractory differentiated TC results. • Lenvatinib shows superior progression-free survival and overall response rate. |
| doi_str_mv | 10.1016/j.ctrv.2015.11.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1752583280</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0305737215002017</els_id><sourcerecordid>1752583280</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-b7648af360c32fc90770a170963da4d55acb6c55edd4abaa24181113a63229933</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVJaTZpvkAPxcdc7MxIlmSXEAghfwoLhbY5C1nSstp6rVSyF_bbV2a3OeSQ0wzDe2-Y3xDyBaFCQHG1qcwYdxUF5BViBcA-kAVyRktshTwhC2DAS8kkPSVnKW0AoGWi_UROqRCy4VgvSLt0w06PfvDdt-Jn6F3hh2Jc72PwtjB6MC4WerBFGNe5S6HP43Hahpg-k48r3Sd3cazn5Pnh_vfdU7n88fj97nZZGk75WHZS1I1eMQGG0ZVpQUrQKKEVzOracq5NJwznztpad1rTGhtEZFowStuWsXNyech9ieHv5NKotj4Z1_d6cGFKCmXe0zDaQJbSg9TEkFJ0K_US_VbHvUJQMzK1UTMyNSNTiCojy6avx_yp2zr7avnPKAuuDwKXr9x5F1Uy3mUy1kdnRmWDfz__5o3d9Bm30f0ft3dpE6Y4ZH4KVaIK1K_5afPPkAPkHMn-AZ00kDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1752583280</pqid></control><display><type>article</type><title>Lenvatinib: Role in thyroid cancer and other solid tumors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cabanillas, Maria E ; Habra, Mouhammed Amir</creator><creatorcontrib>Cabanillas, Maria E ; Habra, Mouhammed Amir</creatorcontrib><description>Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodine-refractory differentiated TC results. • Lenvatinib shows superior progression-free survival and overall response rate.</description><identifier>ISSN: 0305-7372</identifier><identifier>EISSN: 1532-1967</identifier><identifier>DOI: 10.1016/j.ctrv.2015.11.003</identifier><identifier>PMID: 26678514</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject><![CDATA[Advanced ; Animals ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma - drug therapy ; Carcinoma - enzymology ; Carcinoma - therapy ; Clinical Trials as Topic ; Combined Modality Therapy ; Differentiated ; Everolimus - administration & dosage ; Hematology, Oncology and Palliative Medicine ; Humans ; Infant ; Iodine Radioisotopes - therapeutic use ; Medullary ; Mice ; Molecular Targeted Therapy ; Multicenter Studies as Topic ; Multikinase ; Neoplasm Proteins - antagonists & inhibitors ; Neoplasms - drug therapy ; Neoplasms - enzymology ; Paclitaxel - administration & dosage ; Phenylurea Compounds - administration & dosage ; Phenylurea Compounds - adverse effects ; Phenylurea Compounds - pharmacology ; Phenylurea Compounds - therapeutic use ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Quinolines - administration & dosage ; Quinolines - adverse effects ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Receptors, Growth Factor - antagonists & inhibitors ; Refractory ; Signal Transduction - drug effects ; Survival ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - enzymology ; Thyroid Neoplasms - therapy ; Thyroidectomy ; Xenograft Model Antitumor Assays]]></subject><ispartof>Cancer treatment reviews, 2016-01, Vol.42, p.47-55</ispartof><rights>The Authors</rights><rights>2015 The Authors</rights><rights>Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-b7648af360c32fc90770a170963da4d55acb6c55edd4abaa24181113a63229933</citedby><cites>FETCH-LOGICAL-c525t-b7648af360c32fc90770a170963da4d55acb6c55edd4abaa24181113a63229933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0305737215002017$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26678514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cabanillas, Maria E</creatorcontrib><creatorcontrib>Habra, Mouhammed Amir</creatorcontrib><title>Lenvatinib: Role in thyroid cancer and other solid tumors</title><title>Cancer treatment reviews</title><addtitle>Cancer Treat Rev</addtitle><description>Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodine-refractory differentiated TC results. • Lenvatinib shows superior progression-free survival and overall response rate.</description><subject>Advanced</subject><subject>Animals</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - enzymology</subject><subject>Carcinoma - therapy</subject><subject>Clinical Trials as Topic</subject><subject>Combined Modality Therapy</subject><subject>Differentiated</subject><subject>Everolimus - administration & dosage</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Infant</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Medullary</subject><subject>Mice</subject><subject>Molecular Targeted Therapy</subject><subject>Multicenter Studies as Topic</subject><subject>Multikinase</subject><subject>Neoplasm Proteins - antagonists & inhibitors</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - enzymology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Phenylurea Compounds - administration & dosage</subject><subject>Phenylurea Compounds - adverse effects</subject><subject>Phenylurea Compounds - pharmacology</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - adverse effects</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Receptors, Growth Factor - antagonists & inhibitors</subject><subject>Refractory</subject><subject>Signal Transduction - drug effects</subject><subject>Survival</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - enzymology</subject><subject>Thyroid Neoplasms - therapy</subject><subject>Thyroidectomy</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0305-7372</issn><issn>1532-1967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9r3DAQxUVJaTZpvkAPxcdc7MxIlmSXEAghfwoLhbY5C1nSstp6rVSyF_bbV2a3OeSQ0wzDe2-Y3xDyBaFCQHG1qcwYdxUF5BViBcA-kAVyRktshTwhC2DAS8kkPSVnKW0AoGWi_UROqRCy4VgvSLt0w06PfvDdt-Jn6F3hh2Jc72PwtjB6MC4WerBFGNe5S6HP43Hahpg-k48r3Sd3cazn5Pnh_vfdU7n88fj97nZZGk75WHZS1I1eMQGG0ZVpQUrQKKEVzOracq5NJwznztpad1rTGhtEZFowStuWsXNyech9ieHv5NKotj4Z1_d6cGFKCmXe0zDaQJbSg9TEkFJ0K_US_VbHvUJQMzK1UTMyNSNTiCojy6avx_yp2zr7avnPKAuuDwKXr9x5F1Uy3mUy1kdnRmWDfz__5o3d9Bm30f0ft3dpE6Y4ZH4KVaIK1K_5afPPkAPkHMn-AZ00kDU</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Cabanillas, Maria E</creator><creator>Habra, Mouhammed Amir</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>Lenvatinib: Role in thyroid cancer and other solid tumors</title><author>Cabanillas, Maria E ; Habra, Mouhammed Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-b7648af360c32fc90770a170963da4d55acb6c55edd4abaa24181113a63229933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Advanced</topic><topic>Animals</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - enzymology</topic><topic>Carcinoma - therapy</topic><topic>Clinical Trials as Topic</topic><topic>Combined Modality Therapy</topic><topic>Differentiated</topic><topic>Everolimus - administration & dosage</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Infant</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Medullary</topic><topic>Mice</topic><topic>Molecular Targeted Therapy</topic><topic>Multicenter Studies as Topic</topic><topic>Multikinase</topic><topic>Neoplasm Proteins - antagonists & inhibitors</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - enzymology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Phenylurea Compounds - administration & dosage</topic><topic>Phenylurea Compounds - adverse effects</topic><topic>Phenylurea Compounds - pharmacology</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - adverse effects</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Receptors, Growth Factor - antagonists & inhibitors</topic><topic>Refractory</topic><topic>Signal Transduction - drug effects</topic><topic>Survival</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - enzymology</topic><topic>Thyroid Neoplasms - therapy</topic><topic>Thyroidectomy</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cabanillas, Maria E</creatorcontrib><creatorcontrib>Habra, Mouhammed Amir</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer treatment reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cabanillas, Maria E</au><au>Habra, Mouhammed Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lenvatinib: Role in thyroid cancer and other solid tumors</atitle><jtitle>Cancer treatment reviews</jtitle><addtitle>Cancer Treat Rev</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>42</volume><spage>47</spage><epage>55</epage><pages>47-55</pages><issn>0305-7372</issn><eissn>1532-1967</eissn><abstract>Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodine-refractory differentiated TC results. • Lenvatinib shows superior progression-free survival and overall response rate.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>26678514</pmid><doi>10.1016/j.ctrv.2015.11.003</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7372 |
| ispartof | Cancer treatment reviews, 2016-01, Vol.42, p.47-55 |
| issn | 0305-7372 1532-1967 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1752583280 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Advanced Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma - drug therapy Carcinoma - enzymology Carcinoma - therapy Clinical Trials as Topic Combined Modality Therapy Differentiated Everolimus - administration & dosage Hematology, Oncology and Palliative Medicine Humans Infant Iodine Radioisotopes - therapeutic use Medullary Mice Molecular Targeted Therapy Multicenter Studies as Topic Multikinase Neoplasm Proteins - antagonists & inhibitors Neoplasms - drug therapy Neoplasms - enzymology Paclitaxel - administration & dosage Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Phenylurea Compounds - pharmacology Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Quinolines - administration & dosage Quinolines - adverse effects Quinolines - pharmacology Quinolines - therapeutic use Receptors, Growth Factor - antagonists & inhibitors Refractory Signal Transduction - drug effects Survival Thyroid Neoplasms - drug therapy Thyroid Neoplasms - enzymology Thyroid Neoplasms - therapy Thyroidectomy Xenograft Model Antitumor Assays |
| title | Lenvatinib: Role in thyroid cancer and other solid tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lenvatinib:%20Role%20in%20thyroid%20cancer%20and%20other%20solid%20tumors&rft.jtitle=Cancer%20treatment%20reviews&rft.au=Cabanillas,%20Maria%20E&rft.date=2016-01-01&rft.volume=42&rft.spage=47&rft.epage=55&rft.pages=47-55&rft.issn=0305-7372&rft.eissn=1532-1967&rft_id=info:doi/10.1016/j.ctrv.2015.11.003&rft_dat=%3Cproquest_cross%3E1752583280%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1752583280&rft_id=info:pmid/26678514&rft_els_id=S0305737215002017&rfr_iscdi=true |